Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Open-label, Non-randomized, Single-arm, Multi-center Dose Titration Study to Investigate the Safety and Efficacy of NT 201 in Subjects Deemed to Require Total Body Doses of 800 U of NT 201 During the Course of the Study for the Treatment of Upper and Lower Limb Spasticity of the Same Body Side Due to Cerebral Causes

Next Previous
X
Search
Trial Profile

Prospective, Open-label, Non-randomized, Single-arm, Multi-center Dose Titration Study to Investigate the Safety and Efficacy of NT 201 in Subjects Deemed to Require Total Body Doses of 800 U of NT 201 During the Course of the Study for the Treatment of Upper and Lower Limb Spasticity of the Same Body Side Due to Cerebral Causes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Muscle spasticity
  • Focus Adverse reactions; Registrational
  • Acronyms TOWER
  • Sponsors Merz Pharmaceuticals GmbH

    • Most Recent Events

    • 08 Jun 2017 Results of a post-hoc analysis evaluating the effectiveness of incobotulinumtoxinA for treating lower limb (LL) spasticity, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 08 Jun 2017 Results of a post-hoc analysis assessing efficacy of botulinum toxin for shoulder spasticity presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 28 Apr 2017 Results of post-hoc analysis (n=109) assessing the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb spasticity, presented at the 69th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top